IngredientsFurostanols (also written as furostanols, furostanolic saponins, or furostanol glycosides) are a major subclass of steroidal saponins — naturally occurring glycosidic secondary metabolites found predominantly in higher plants. The furostane skeleton consists of a five-ring steroidal structure in which C22–26 forms an open chain and the C26 position carries a hydroxyl group, distinguishing it from the spirostane type; steroid glycosides of this class contain 27 carbon atoms and are modified triterpenoids whose aglycone is a steroid attached to one or more sugar molecules.
These steroidal glycosides may be used in the partial synthesis of sex hormones or other steroids, and the class of steroid saponins has been further divided into spirostanol and furostanol saponins. The furostanol skeleton differs critically from the spirostanol skeleton: furostanol saponins (e.g., protodioscin) result from glycosylation modification at C3-OH and/or C26-OH of the 22R-hydroxy-furostane backbone with the opening of the F ring, while spirostanol saponins feature a closed F-ring steroidal skeleton also requiring C3-OH-glycosyl modification.
Both furostanol and spirostanol types of steroidal saponins are derived from either the 30-carbon linear precursor 2,3-oxidosqualene (cycloartenol pathway) or 22,26-dihydroxycholesterol (cholesterol pathway), but during synthesis of their steroidal aglycone the loss of three methyl groups results in a 27-carbon backbone. The interconversion between the two forms is enzymatically regulated: conversion of furostanol saponin into spirostanol form and vice versa is catalyzed by furostanol glycoside 26-O-β-glucosidase (F26G) and UDP-glucosyltransferase (UGT) enzymes, respectively.
Saponins are also classified as monodesmosides (one sugar chain), bisdesmosides (two chains), or trisdesmosides (three chains) based on the number of sugar chains directly bound with the aglycone. Furostanol saponins are typically bisdesmosidic, carrying sugar chains at both C3 and C26 positions of the aglycone. Two types of steroidal saponins — spirostanol and furostanol — are distributed within monocotyledons from the Asparagaceae, Costaceae, Poaceae, Dioscoreaceae, and Liliaceae, as well as dicotyledons from the Solanaceae or Fabaceae.
Key individual furostanol saponins and aglycones of pharmacological relevance include protodioscin, protogracillin, methyl protodioscin, protoneodioscin, and the aglycone (sapogenin) diosgenin. Current production of diosgenin mainly depends on the acid hydrolysis of steroidal saponins from Dioscorea plants; in China especially, Dioscorea zingiberensis is used. The steroidal saponins, which are the principal constituents of fenugreek seeds, can significantly induce hypoglycemia and hypocholesterolemia; fenugreek seeds abound in furostanol saponins, with spirostanol saponins present only in small amounts.
Furostanols are a class of naturally occurring steroidal saponins found in a variety of plants, most notably in fenugreek (Trigonella foenum-graecum) and certain species of the Dioscorea (yam) genus. Additional botanically confirmed sources include:
Furostanols are commercially available as standardized botanical extracts, either as single-herb preparations or as components of multi-herb formulas. Key commercial extract forms include:
Various natural preparations of furostanolic saponins based on extracts of these source plants are available commercially, but suffer from the limitation of variation in therapeutic efficacy due to large variation in the content of active compounds or bioactive fractions.
In both Ayurvedic and Chinese medicine, fenugreek leaves and seeds have long been known for their therapeutic efficacy in diabetes, muscle building, and wrestling. Ancient Ayurvedic texts mention the use of furostanol-rich herbs for enhancing vitality, supporting reproductive health, and promoting general well-being; fenugreek seeds, abundant in furostanol saponins, were utilized to support lactation, improve digestion, and manage blood sugar levels.
Asparagus racemosus (Shatavari), commonly known as the "Queen of Herbs," is a reservoir of alleviative properties in the traditional Ayurvedic system of medicine. It is regarded as a rasayana (rejuvenating tonic) and part of 64 formulations in Ayurveda, used as a health tonic for the treatment of a wide range of clinical manifestations including cancer, immune disorders, and female reproductive health-related issues. Asparagus racemosus has also been described for use as an antioxidant, antidyspepsia, antitussive, and immune stimulant, as well as in the treatment of kidney disorders, chronic fever, liver conditions, stomach ulcers, and for increasing milk secretion. Its medicinal usage has been reported in the Indian and British Pharmacopoeias and in traditional systems of medicine such as Ayurveda, Unani, and Siddha.
Tribulus terrestris is a perennial plant widely distributed around the world, especially in subtropical areas. Its dried fruit, named "Jili" in Chinese, has been used as a traditional Chinese medicine (TCM) for the treatment of edema, abdominal distention, emission, morbid leucorrhea, and vitiligo. Additionally, it has been used as an aphrodisiac tonic, antibacterial agent, and for the treatment of cardiovascular diseases.
Asparagus cochinchinensis, known as "Tianmendong" in China, has seen its roots used in Chinese folk medicine for the treatment of cough, acute and chronic bronchitis, chronic pharyngitis, hemorrhoids, and tumors for thousands of years.
Balanites aegyptiaca (Zygophyllaceae) fruits are a well-known antidiabetic drug in Egyptian folk medicine. Tribulus terrestris has also served as an Ayurvedic tonic and aphrodisiac, and has been used in European folk medicine to increase sexual potency.
Traditional preparations of furostanol-containing botanicals vary by culture. Fenugreek seeds were commonly incorporated as a spice and food ingredient: fenugreek leaves (dried or fresh) and seeds are used as vegetable spices and condiments in Indian cuisine; being an important part of the diet, fenugreek contributes substantially to nutrient intake and has considerable medicinal value. Decoctions and water preparations were the simplest traditional forms — one documented preparation for fenugreek seeds involved boiling soaked seeds in water for 5–7 minutes. In China, fenugreek seeds have long been used as a traditional medicine for tonic and stomachic purposes.
The best-characterized furostanol saponins across commercially relevant sources are:
Hormonal / Steroidogenic Modulation: The hydrolyzed saponins are transformed into steroidal sapogenins, with antispasmodic and natriuretic properties, and are proposed to increase the production of luteinizing hormone (LH), testosterone, estrogen, and other steroids. Protodioscin was believed to elicit the release of luteinizing hormone from the pituitary gland, which in turn activates the synthesis of testosterone by Leydig cells. Protodioscin is proposed to be converted by the adrenal glands into DHEA (dehydroepiandrosterone), which constitutes the raw material for the production of testosterone, estrogens, and other hormones. Fenugreek's saponins, particularly protodioscin and furostanol glycosides, may support endogenous testosterone production by influencing steroidogenesis and modulating key enzymes like aromatase and 5-alpha reductase.
Antidiabetic Mechanisms: Dietary saponins possess multidirectional anti-diabetic capabilities through concurrent regulation of various signaling pathways, such as IRS-1/PI3K/Akt, AMPK, Nrf2/ARE, NF-κB-NLRP3, SREBP-1c, and PPARγ, in the liver, pancreas, gut, and skeletal muscle. More specifically for furostanol saponins, the effect of furoasparoside E (from A. racemosus) on GLUT4 translocation was found to be mediated by the AMPK-dependent signaling pathway in L6-GLUT4myc myotubes. Additionally, saponins are known for inhibiting α-amylase, α-glucosidase enzymes, and aldose reductase, which are key enzymes for managing T2D by lowering carbohydrate absorption in the small intestine and colon. A furostanol saponin from Balanites aegyptiaca demonstrated significant α-glucosidase and aldose reductase inhibitory activities (IC₅₀ = 3.12 ± 0.17 and 1.04 ± 0.02 µg/mL, respectively).
Hemolytic Properties: An important structural note is that for steroid saponins, most studies conclude that furostanols are in general hemolytically inactive — in contrast to spirostanol saponins, which are known to have hemolytic potential. This distinction has implications for their relative safety profile.
Cytotoxic Activity (Preclinical): Among twenty compounds (including saponins, sapogenins, and sterols) isolated from Paris polyphylla, only furostanols were active against human CCRF-CEM leukemia cells, and their activity was highly potent, while both spirostanol saponins and sterols lacked any effect on this cell line.
Hematopoietic Stem Cell Expansion: Furostanol saponins from Trillium tschonoskii were tested for their effect on the expansion of human cord blood CD34+ hematopoietic stem and progenitor cells; treatment with several of the isolated compounds showed increased numbers of rigorously phenotype-defined hematopoietic stem cells, and some demonstrated enhanced ability to increase percentages and numbers of CD34+CD38− cells and multipotential progenitors — the first report that furostanol saponins from this source can promote hematopoietic stem/progenitor cell (HSPC) expansion.
Clinical Evidence: The most robust clinical evidence for furostanolic saponins in glucose regulation comes from fenugreek extracts. A multicenter, randomized, placebo-controlled, double-blind, add-on clinical study evaluated over 90 consecutive days the efficacy of Fenfuro (daily dosage: 500 mg twice daily) in 154 subjects (male: 108; female: 46; age: 25–60 years) with type 2 diabetes. The study examined fasting and post-prandial plasma glucose, glycosylated hemoglobin (HbA1c), and C-peptide levels. In the Fenfuro-treated group, 48.8% of subjects reported reduced dosage of anti-diabetic therapy.
A subsequent randomized double-blind placebo-controlled trial of the same extract found that administration of a daily dosage of 500 mg × 2 for 12 weeks resulted in significant decreases in fasting and post-prandial glucose as well as glycated hemoglobin, with no adverse effects as revealed by C-peptide analysis, TSH levels, and other immunohematological parameters.
A number of studies have demonstrated that fenugreek attenuated body weight gain and improved insulin sensitivity; the anti-diabetic efficacy of fenugreek seed extract was attributed to the presence of furostanolic saponins and 4-hydroxyisoleucine.
Preclinical Evidence: An in vivo antidiabetic study of a furostanol saponin from Balanites aegyptiaca in streptozotocin-induced diabetic rats at 200 mg/kg revealed reduction of fasting plasma glucose by 51.39%, reduction of total cholesterol by 31.90%, and increment in insulin and C-peptide levels by 63.56% and 65%, respectively. Furoasparoside E from Asparagus racemosus produced a notable decrease in postprandial blood glucose in leptin receptor-deficient db/db mice (a type 2 diabetes model); its effect on GLUT4 translocation was mediated by the AMPK-dependent signaling pathway; it also demonstrated higher bioavailability and efficacy in in vivo pharmacokinetic studies.
Evidence Strength: Moderate for fenugreek-derived furostanolic saponins in T2D, supported by multiple small-to-medium-sized randomized controlled trials. Preclinical data are promising but most mechanistic work remains animal and in vitro. Independent large-scale trials are limited.
Clinical Evidence: A clinical investigation in 49 resistance-trained male subjects demonstrated that fenugreek seed extract (500 mg/day) had a significant impact on both upper- and lower-body strength and body composition in a double-blind placebo-controlled study. Steels et al. conducted a randomized, double-blind, placebo-controlled study in 60 healthy males (age: 25–52 years; daily dose of fenugreek seed extract: 600 mg) over a period of 6 weeks.
A meta-analysis of clinical trials noted that fenugreek extract has a significant effect on total serum testosterone; results from clinical trials suggest that fenugreek extract supplement has an effect on serum total testosterone levels in males. Different types of glycoside extracts of fenugreek have shown androgenic and anabolic effects in males; a total of four trials were included in the meta-analysis, and fenugreek extract showed a significant effect on total serum testosterone.
For T. terrestris: When given at a dose of 750 mg per day for 5 days, Tribulus increased serum FSH and estradiol when compared with baseline in females, and increased LH and testosterone in males, in open-label clinical trials. However, in animal studies, Tribulus increased sex hormones (e.g., testosterone) and improved nitric oxide synthesis; these results have not been observed in some human studies, explained partly by differences in extract and plant parts and the fact that studies included healthy males with normal testosterone. Oral administration of tribulus at a dose of 3.21 mg/kg body weight had no significant effect on body composition or exercise performance in resistance-trained subjects; other research suggested that T. terrestris extracts did not increase body mass and testosterone levels, but they increased anaerobic performance of trained boxers and gave relief to muscle damage.
In one clinical study of men with erectile dysfunction: Kamenov et al. evaluated the efficacy and safety of a standardized extract (Tribestan®, containing 250 mg dry extract equivalent to furostanol saponins not less than 112.5 mg) for the treatment of men with mild to moderate erectile dysfunction and with or without hypoactive sexual desire disorder, in a prospective, phase IV, randomized, double-blind, placebo-controlled clinical trial in parallel groups.
Regarding male fertility: A human randomized trial of 30 male patients with idiopathic infertility found no significant improvement in levels of testosterone or semen parameters after 3 months of treatment with Tribulus (750 mg/day). However, a trial of 65 men with abnormal semen evaluation found that administering Androsten (250 mg dried extract per capsule, including 37.5 mg protodioscin) three times per day over 12 weeks resulted in a significant enhancement of sperm count.
Evidence Strength: Preliminary to moderate, and results are mixed. A significant factor is that furostanol saponin content varies substantially by geographic origin of plant material. All of the data and clinical outcomes have been based on a leaf extract from Bulgaria, which has been shown to be highest in protodioscin; if a Tribulus product is made from the root or fruit of the plant or is obtained from anywhere other than Eastern Europe, it will probably contain low levels of protodioscin. Most testosterone-supporting effects in fenugreek are from small-to-medium RCTs, often proprietary extract-funded.
Clinical Evidence: An open-label, one-arm, non-randomized, post-marketing surveillance study was conducted in 50 premenopausal women (18–45 years, BMI <42) diagnosed with PCOS using Furocyst (2 capsules of 500 mg each/day), a novel fenugreek seed extract enriched in approximately 40% furostanolic saponins, over 90 consecutive days, to determine its efficacy on the reduction of ovarian volume and the number of ovarian cysts. After treatment for three months with Furocyst, there was significant reduction in ovary volume; 46% of the study population showed reduction in cyst size who had larger cysts; 36% showed complete dissolution of cysts who had small cysts; 12% got pregnant; and 71% reported regular menstrual cycle on completion of treatment, with LH:FSH ratio reduced to normal.
A later single-blinded, randomized clinical study examined lipid profile and insulin resistance: The study was conducted among 230 patients between 18 and 45 years of age presenting for PCOS treatment; after screening for eligibility, patients were randomized into the experimental group (receiving Furocyst BD for three months) and a placebo group. After 12 weeks of treatment, a significant weight reduction and consequent reduction in BMI were observed in obese patients receiving Furocyst.
Evidence Strength: Preliminary. The initial PCOS trial lacked a randomized control arm, limiting causal inference. The subsequent larger study was single-blinded. Independent replication in double-blind RCTs is needed.
In one clinical study, daily administration of fenugreek seed powder for 30 days resulted in statistically significant reductions in total cholesterol, LDL-C, and triglycerides, along with a marked increase in HDL-C, consistent with the hypolipidemic effects of fenugreek's bioactive compounds, particularly steroidal saponins and polyphenols, that modulate lipid metabolism and reduce cardiovascular risk in diabetic individuals.
A saponin-rich fenugreek extract can generate multi-bioactive extracts that inhibit pancreatic lipase and cholesterol bioaccessibility, potentially leading to a hypocholesterolemic effect. Preclinical investigation in rats also demonstrated that furostanol saponin from Balanites aegyptiaca reduced total cholesterol by 31.90% at 200 mg/kg.
Evidence Strength: Preliminary clinical evidence exists, largely embedded in trials primarily designed to assess glycemic outcomes. No large cardiovascular endpoint trials with furostanol-standardized extracts have been published.
The furostanol protoneodioscin (NSC-698789), isolated from the rhizomes of Dioscorea species, showed high activity against multiple cancer cell lines — including leukemia (CCRF-CEM, K562, MOLT-4), colon cancer (HCT-15, KM12), CNS cancer (SNB-75), melanoma (M14), renal cancer (CAKI-1), prostate cancer (DU-145), and breast cancer (MDA-MB-435) — with GI₅₀ ≤ 2.0 µmol/L. Leukemia, CNS cancer, and prostate cancer appeared the most sensitive subpanels to protoneodioscin. A comparison with other compounds in the NCI's database indicated that protoneodioscin had a novel mechanism of anticancer action.
Methyl protodioscin (a furostanol compound) and dioscin (a spirostanol glycoside), isolated from the root of Polygonatum zanlanscianense, were tested against human leukemia HL-60 cells in vitro; the spirostanol glycoside induced differentiation, apoptosis, and cytotoxicity in the HL-60 cells, while the furostanol had no effect — suggesting that the spirostanol structure is critical in the effects on this particular cell line.
Evidence Strength: Entirely preclinical (in vitro and animal models). No human clinical trials have evaluated furostanol saponins as anticancer agents. Results vary by individual compound and cell line.
All isolated furostanol saponins from T. tschonoskii were tested for their effect on expansion of human cord blood CD34+ hematopoietic stem and progenitor cells; multiple compounds showed increased numbers of hematopoietic stem cells; notably, several compounds demonstrated enhanced ability to increase percentages and numbers of CD34+CD38− cells and multipotential progenitors — marking the first report that furostanol saponins from this source can promote hematopoietic stem/progenitor cell (HSPC) expansion.
Evidence Strength: In vitro only. No human trials reported.
Tribulus terrestris contains various bioactive metabolites including steroidal saponins, flavonoids, and alkaloids; these metabolites exhibit anti-inflammatory, antioxidant, and antibacterial properties, making T. terrestris a candidate for treating multiple skin disorders; studies have shown its potential efficacy against conditions such as atopic dermatitis, acne, and vitiligo, though precise mechanisms are not yet fully elucidated and there is a lack of high-quality, large-scale clinical trials.
Furostanols are studied as components of standardized botanical extracts, not as isolated pure compounds. The following dosages are drawn exclusively from published studies:
The most common adverse effect of fenugreek (the predominant dietary supplement source of furostanol saponins) was mild gastrointestinal discomfort following oral consumption. Other reported effects included hypoglycemia, potential hypokalemia, allergic reactions, and a maple syrup odor in the urine, sweat, or skin of infants and mothers. Fenugreek is generally considered safe, with most reported side effects being mild and self-limiting; no fatalities have been attributed to its use.
In the Fenfuroâ„¢ multicenter RCT: No significant adverse effects were observed by blood chemistry analyses. In the Furocyst PCOS trial: No changes were observed in liver function test, kidney function test, and hemogram levels.
Dizziness associated with fenugreek use might result from a significant decrease in systolic blood pressure or from hypoglycemia-induced neurological symptoms due to its activity on insulin receptors. The blood glucose-lowering activity of furostanolic saponins is documented in clinical and preclinical studies, and this has direct implications when fenugreek is co-administered with antidiabetic medications: fenugreek might lower blood sugar; diabetes medications are also used to lower blood sugar; taking fenugreek along with diabetes medications might cause blood sugar to go too low. Relevant medications include sulfonylureas (glimepiride, glyburide, glipizide, tolbutamide, chlorpropamide), insulin, and thiazolidinediones (pioglitazone, rosiglitazone).
Documented adverse events for fenugreek include suspected hypokalemia, alongside hypoglycemia, allergic reactions, and a maple syrup-like odor in sweat or urine.
Ten case reports or case series have detailed allergic reactions or hypersensitivity signs and symptoms associated with fenugreek consumption. These included allergic reactions or hypersensitivity signs and symptoms reported in 10 case reports.
Concomitant use of fenugreek with antiarrhythmic drugs, diuretics, and laxatives has been noted as a potential interaction concern in the adverse effects literature. The additive blood glucose-lowering effect with antidiabetic agents is the most clinically documented interaction risk based on available evidence.
In one clinical trial of T. terrestris extract in menopausal women: there was no significant difference in adverse effects between the active treatment and placebo groups. Available safety data for Tribulus-derived furostanols in humans are limited primarily to short-duration trials.
A critical practical safety and efficacy concern noted in the literature is extreme variability in furostanol content across commercial products. Various natural preparations of furostanolic saponins based on extracts of source plants are available commercially, but suffer from the limitation of variation in therapeutic efficacy due to large variation in the content of active compounds or bioactive fractions. This variability makes comparison of outcomes across studies, and dose-response conclusions, difficult to establish.
Health conditions that Furostanols may help support.
Body systems that Furostanols may help support.
Go back